Log in to your Inderes Free account to see all free content on this page.

Lumito

0.514

SEK

+4.26 %

LUMITO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Be the first to follow this company

+4.26%

+2.39%

-34.85%

-48.34%

-67.83%

-64.31%

-31.65%

-89.94%

-61.2%

Lumito specializes in medical technology for digital pathology. The company strives to improve tissue diagnostics with its patented technology based on upconverted nanoparticles. The company plans to initially launch its first product for research laboratories. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito has its headquarters in Lund.

Market cap

136.67M SEK

Turnover

587.44K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

20.2.

2025

Annual report '24

8.5.

2025

Interim report Q1'25

22.8.

2025

Interim report Q2'25

ShowingAll content types

Regulatory press release12/19/2024, 10:15 AM

Lumito and Truly Labs join forces to drive innovation and enhanced competitiveness in tissue analysis

Regulatory press release11/28/2024, 12:30 PM

Lumito focus on the accelerated commercialisation of SCIZYS and are initiating a cost-reduction programme

Regulatory press release11/28/2024, 11:00 AM

Lumito refinances loan of SEK 12.5 million

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/18/2024, 6:55 PM

Warrants of series TO6 were subscribed to approximately 94 percent and Lumito receives approximately SEK 12.6 million

Regulatory press release11/12/2024, 9:45 AM

Members of Lumitos board and management team intend to exercise warrants of series TO6

Regulatory press release11/12/2024, 7:00 AM

The last day of trading with the warrants of series TO6 in Lumito AB is today, November 12, 2024

Press release11/4/2024, 10:00 AM

Lumito will present at the BioStock Life Science Summit, November 20

Regulatory press release11/4/2024, 7:20 AM

The subscription price for exercise of warrants of series TO6 in Lumito AB is set to SEK 0.39 and the subscription period commences today November 4, 2024

Regulatory press release10/31/2024, 7:45 AM

Lumito AB publishes Quarterly Report 3, 2024

Regulatory press release10/15/2024, 10:15 AM

Lumito signs Letter of Intent with Scientific Advisor

Regulatory press release10/11/2024, 12:10 PM

Lumito AB signs a Letter of Intent with Katana Labs GmbH

Regulatory press release8/23/2024, 6:30 AM

Lumito AB publishes Quarterly Report 2, 2024

Regulatory press release7/5/2024, 6:45 AM

Lumito has CE-marked its first product SCIZYS

Regulatory press release6/11/2024, 11:00 AM

Warrants of series TO5 were subscribed to approximately 79.2 percent and Lumito receives approximately SEK 20.4 million

Regulatory press release6/4/2024, 6:45 AM

The last day of trading with the warrants of series TO5 in Lumito AB is today, June 4, 2024

Regulatory press release5/27/2024, 6:45 AM

The subscription price for exercise of warrants of series TO5 in Lumito AB is set to SEK 0.75 and the subscription period commences today May 27

Regulatory press release5/7/2024, 8:30 AM

Lumito AB publishes Quarterly Report 1, 2024

Regulatory press release2/22/2024, 7:45 AM

Lumito AB publishes Quarterly Report 4, 2023

Press release2/6/2024, 9:00 AM

Research group at the Tyndall National Institute got an article published on the use of up-converting nanoparticles

Regulatory press release12/22/2023, 4:17 PM

Conversion of paid subscribed units (BTU) and first day of trading with warrants of series TO5 and TO6

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.